KXA
RAPT

KPCB XV Associates’s RAPT Therapeutics RAPT Stock Holding History

KPCB XV Associates’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$15.6M Sell
81,066
-81,067
-50% -$15.3M 43.54% 1
2022
Q2 		$23.7M Hold
162,133
– – 43.66% 1
2022
Q1 		$28.5M Hold
162,133
– – 36.91% 2
2021
Q4 		$47.6M Hold
162,133
– – 37.58% 2
2021
Q3 		$40.3M Hold
162,133
– – 30.08% 2
2021
Q2 		$41.2M Sell
162,133
-81,250
-33% -$15.2M 18.41% 3
2021
Q1 		$43.2M Hold
243,383
– – 18.62% 3
2020
Q4 		$38.5M Buy
+243,383
New +$52.9M 16.52% 2

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

KPCB XV Associates's RAPT Position: Q3 2022 in Review

KPCB XV Associates reduced its RAPT Therapeutics (RAPT) stake by 50% in Q3 2022, selling an estimated $15.3M and leaving 81,066 shares worth $15.6M. The position accounts for 43.54% of the portfolio, ranked #1.

KPCB XV Associates first reported a position in RAPT in Q4 2020 and has held it in 8 quarters since. The position peaked at $47.6M in Q4 2021. 98 funds tracked by Wall St. Rank hold RAPT as of Q3 2022.

  • KPCB XV Associates held 81,066 shares of RAPT Therapeutics worth $15.6M as of Q3 2022.
  • KPCB XV Associates sold 81,067 RAPT Therapeutics shares in Q3 2022, an estimated $15.3M.
  • RAPT Therapeutics made up 43.54% of KPCB XV Associates's portfolio in Q3 2022, its #1 holding.
  • KPCB XV Associates first reported a position in RAPT Therapeutics in Q4 2020 and has held it in 8 quarters since.
  • KPCB XV Associates's RAPT Therapeutics position peaked at $47.6M in Q4 2021.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2022.

Based on KPCB XV Associates's 13F filing for Q3 2022, filed 26 Oct 2022.